Nykredit A S Invests $8.06 Million in DexCom, Inc. $DXCM

Key Points

• Nykredit A/S acquired a new $8.06 million stake in DexCom, purchasing 119,636 shares during the second quarter. Institutional investors collectively own 97.75% of DXCM’s outstanding shares.
• DexCom’s latest quarterly results exceeded expectations, with earnings of $0.70 per share versus the $0.61 consensus estimate and revenue of $1.31 billion, up 13.1% year over year.
• Insiders sold 73,504 shares worth $5.65 million over the past three months, while analysts maintained a “Moderate Buy” consensus rating and an average price target of $89.08.

Nykredit A S purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 119,636 shares of the medical device company's stock, valued at approximately $8,057,000.

Several other institutional investors also recently modified their holdings of DXCM. Plato Investment Management Ltd bought a new position in DexCom during the second quarter valued at approximately $782,000. Aurora Investment Counsel bought a new stake in DexCom in the 2nd quarter worth approximately $2,340,000. E Fund Management Co. Ltd. bought a new stake in DexCom in the 2nd quarter worth approximately $1,273,000. Silvant Capital Management LLC purchased a new stake in DexCom during the 2nd quarter valued at $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in DexCom during the 2nd quarter valued at $89,940,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, Director Mark Foletta sold 2,000 shares of DexCom stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director directly owned 48,852 shares of the company's stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the business's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares in the company, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,504 shares of company stock worth $5,651,332. Insiders own 0.28% of the company's stock.

DexCom Stock Down 0.2%

NASDAQ DXCM opened at $89.17 on Tuesday. The stock's 50 day moving average is $84.36 and its 200 day moving average is $73.39. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The stock has a market cap of $33.65 billion, a PE ratio of 35.25, a P/E/G ratio of 1.50 and a beta of 1.42.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period last year, the firm posted $0.48 EPS. The company's revenue was up 13.1% on a year-over-year basis. Research analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. Royal Bank Of Canada raised their price target on DexCom from $85.00 to $90.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Piper Sandler reiterated an "overweight" rating and set a $95.00 price objective (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the company a "buy" rating in a report on Monday, August 3rd. Stifel Nicolaus set a $95.00 price objective on shares of DexCom and gave the stock a "buy" rating in a report on Friday, July 31st. Finally, Truist Financial set a $102.00 price target on shares of DexCom and gave the stock a "buy" rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $89.08.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.